SCHEMBL25925699

SCHEMBL25925699

CC(=O)NCCNc1nc(C)cc(C(=O)O)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
KDM4E B2RXH2 1/20 0.53
GAA P10253 2/20 0.45
MAPK1 P28482 2/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.40
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
PDCD1 Q15116 3/20 0.39
CD274 Q9NZQ7 3/20 0.39
CA12 O43570 1/20 0.38
CA4 P22748 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CYP1A2 P05177 4/20 0.38
CLK4 Q9HAZ1 3/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30270571 1.00 KMT2A (0.53) KMT2AKDM4EGAAMAPK1MEN1
SCHEMBL1178661 0.83 KDM4E (0.57) KMT2AKDM4EGAAMAPK1MEN1
SCHEMBL25925015 0.82 KMT2A (0.47) KMT2AKDM4EGAAMAPK1MEN1
SCHEMBL1180020 0.80 KMT2A (0.51) KMT2AKDM4EGAAMAPK1MEN1
SCHEMBL2713871 0.78 CYP1A2 (0.58) KMT2AKDM4EMAPTADORA1CYP1A2
SCHEMBL24124930 0.78 L3MBTL1 (0.43) KMT2AKDM4EGAAMAPK1MEN1
SCHEMBL1178977 0.76 ESR1 (0.49) KMT2AKDM4EGAAMAPK1MEN1
SCHEMBL1180441 0.74 MAPT (0.44) KMT2AKDM4EMAPK1MEN1MAPT
SCHEMBL24124889 0.74 KDM4E (0.53) KMT2AKDM4EGAAMAPK1MEN1
SCHEMBL24124891 0.74 LMNA (0.43) KMT2AKDM4ECYP1A2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 KMT2A 578/4885KDM4E 204/4885GAA 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.